National Institute on Drug Abuse; Notice of Closed Meeting, 56834-56835 [2017-25787]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
56834
Federal Register / Vol. 82, No. 229 / Thursday, November 30, 2017 / Notices
Officer, Indian Health Service, 5600
Fishers Lane, Rockville, MD 20857.
• Phone: 301–443–4750.
• Email: Evonne.Bennett-Barnes@
ihs.gov.
• Fax: 301–443–4750.
SUPPLEMENTARY INFORMATION: Title:
OMB Control No. 0917–0036, Fast Track
Generic Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery: IHS Customer Service
Satisfaction and Similar Surveys.
Abstract: The IHS will be engaging in
information collection activities that
will garner qualitative customer and
stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery within
Federal Agencies. Qualitative feedback
is information that provides useful
insights on perceptions and opinions,
but are not statistical surveys that yield
quantitative results that can be
generalized to the population of study.
This feedback will provide insight into
customer or stakeholder perceptions,
opinions, experiences and expectations,
and provide an early warning of issues
with service. Also, the collection of
qualitative feedback will assist IHS to
focus its attention on areas where
communication, training, or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing, collaborative and
actionable communications between the
Agency and its customers and
stakeholders. Furthermore, the
collection activity will allow feedback
to contribute directly to the
improvement of program management.
Feedback or information collected
under this generic clearance will
provide useful information, but it will
not yield data that can be generalized to
the overall population. This type of
generic clearance for qualitative
collection will not be used for
quantitative information collections that
are designed to yield reliably actionable
results, such as monitoring trends over
time or documenting program
performance. Such data uses require
more rigorous designs that address: the
target population to which
generalizations will be made, sampling
frame, sample design (including
stratification and clustering), precision
requirements or power calculations that
justify the proposed sample size, the
expected response rate, methods for
assessing potential non-response bias,
protocols for data collection, and any
testing procedures that were or will be
undertaken prior fielding the study.
Depending on the degree of influence
the results are likely to have, such
VerDate Sep<11>2014
18:35 Nov 29, 2017
Jkt 244001
collections may still be eligible for
submission for other generic
mechanisms that are designed to yield
quantitative results. Below are the IHS
projected average estimates for the next
three years: 1
Current Actions: Extension of
approval for a collection of information.
Type of Review: Extension.
Affected Public: Individuals and
households, businesses and
organizations, and Tribal Government.
Average expected annual number of
activities: 100.
Respondents: 105,000.
Annual responses: 105,000.
Frequency of response: Once per
request.
Average minutes per response: 10.
Burden hours: 17,500.
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid OMB
control number.
Dated: November 17, 2017.
Michael D. Weahkee,
Assistant Surgeon General, U.S. Public Health
Service, Acting Director, Indian Health
Service.
[FR Doc. 2017–25815 Filed 11–29–17; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
1 The 60-day notice included the following
estimate of the aggregate burden hours for this
generic clearance for IHS federal-wide:
Average expected annual number of activities:
100.
Average number of respondents per activity:
1,050.
Annual responses: 105,000.
Frequency of response: Once per request.
Average minutes per response: 10.
Burden hours: 17,500.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
I Review.
Date: January 25–26, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Cambria Hotel & Suite Rockville, 1
Helen Heneghan Way, Rockville, MD 20850.
Contact Person: David G. Ransom, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W124,
Bethesda, MD 20892–9750, 240–276–6351,
david.ransom@nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
F—Institutional Training and Education.
Date: February 26–27, 2018.
Time: 7:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Timothy C. Meeker, MD,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W642, Bethesda, MD 20892–9750,
240–276–6464, meekert@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 24, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25785 Filed 11–29–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
E:\FR\FM\30NON1.SGM
30NON1
Federal Register / Vol. 82, No. 229 / Thursday, November 30, 2017 / Notices
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research (R21).
Date: December 15, 2017.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4242, MSC 9550, Bethesda,
MD 20892, 301–827–5833, ivan.navarro@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: November 24, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25787 Filed 11–29–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
daltland on DSKBBV9HB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict.
Date: December 12, 2017.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Mike Radtke, Ph.D.,
Scientific Review Officer, Center for
VerDate Sep<11>2014
19:42 Nov 29, 2017
Jkt 244001
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4176,
MSC 7806, Bethesda, MD 20892, 301–435–
1728, radtkem@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 24, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25784 Filed 11–29–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of
meetings of the National Advisory
Allergy and Infectious Diseases Council.
The meetings will be open to the public
as indicated below, with attendance
limited to space available. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Allergy and Infectious Diseases Council.
Date: January 29, 2018.
Open: 10:30 a.m. to 11:40 a.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1/E2,
45 Center Drive, Bethesda, MD 20892.
Closed: 11:40 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1/E2,
45 Center Drive, Bethesda, MD 20892.
Contact Person: Matthew J. Fenton, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Allergy and Infectious
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
56835
Diseases, 5601 Fishers Lane, Rm 4F50
Bethesda, MD 20892, 301–496–7291,
fentonm@niaid.nih.gov.
Name of Committee: National Advisory
Allergy and Infectious Diseases Council;
Allergy, Immunology and Transplantation
Subcommittee.
Date: January 29, 2018.
Closed: 8:30 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Conference Room D, 45
Center Drive, Bethesda, MD 20892.
Open: 1:00 p.m. to adjournment.
Agenda: Reports from the Division Director
and other staff.
Place: National Institutes of Health,
Natcher Building, Conference Room D, 45
Center Drive, Bethesda, MD 20892.
Contact Person: Matthew J. Fenton, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rm 4F50,
Bethesda, MD 20892, 301–496–7291,
fentonm@niaid.nih.gov.
Name of Committee: National Advisory
Allergy and Infectious Diseases Council;
Microbiology and Infectious Diseases
Subcommittee.
Date: January 29, 2018.
Closed: 8:30 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Conference Rooms
F1/F2, 45 Center Drive, Bethesda, MD 20892.
Open: 1:00 p.m. to adjournment.
Agenda: Reports from the Division Director
and other staff.
Place: National Institutes of Health,
Natcher Building, Conference Rooms F1/F2,
45 Center Drive, Bethesda, MD 20892.
Contact Person: Matthew J. Fenton, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rm 4F50,
Bethesda, MD 20892, 301–496–7291,
fentonm@niaid.nih.gov.
Name of Committee: National Advisory
Allergy and Infectious Diseases Council;
Acquired Immunodeficiency Syndrome
Subcommittee.
Date: January 29, 2018.
Closed: 8:30 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Conference Room A, 45
Center Drive, Bethesda, MD 20892.
Open: 1:00 p.m. to adjournment.
Agenda: Program advisory discussions and
reports from division staff.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1/E2,
45 Center Drive, Bethesda, MD 20892.
Contact Person: Matthew J. Fenton, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rm 4F50,
Bethesda, MD 20892, 301–496–7291,
fentonm@niaid.nih.gov.
Name of Committee: National Advisory
Allergy and Infectious Diseases Council;
Allergy, Immunology and Transplantation
Subcommittee.
E:\FR\FM\30NON1.SGM
30NON1
]]>Agencies
[Federal Register Volume 82, Number 229 (Thursday, November 30, 2017)]
[Notices]
[Pages 56834-56835]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25787]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant
[[Page 56835]]
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research
(R21).
Date: December 15, 2017.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892,
301-827-5833, ivan.navarro@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: November 24, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-25787 Filed 11-29-17; 8:45 am]
BILLING CODE 4140-01-P
